Trial Watch Edition 16 captures high signal clinical development activity from August 16 to August 31, 2026.
This edition is defined by one of the strongest sponsor concentration signals so far. AstraZeneca opened four large Phase 3 programs in a single two week window, spanning kidney disease, heart failure, obesity and multiple myeloma.
At the same time, Regeneron expanded its Factor XI program into another indication, Pfizer moved further into active comparator immunology testing, and Myeloid Therapeutics opened an in vivo CAR T program in autoimmune disease.
The broader signal is clear. Clinical development is moving into larger studies, sharper competitive comparisons and platform level execution across multiple therapy areas.